Metformin Pharmconsul

Metformin Hydrochloride, the active ingredient in Metformin Pharmconsul, is a Biguanide presented as a tablet for oral use. It reduces hepatic glucose production and improves insulin sensitivity, treating type 2 diabetes mellitus in adults.

GNH USA supplies Metformin Pharmconsul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Pharmconsul belongs to the biguanide class and is used to manage disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes: delays progression to overt diabetes by enhancing insulin sensitivity. - Gestational diabetes mellitus: used as an adjunct to diet therapy to control maternal hyperglycaemia when insulin is not required.

Metformin Pharmconsul may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare events can be serious.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Diarrhoea: frequent loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or pain in the abdomen. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: abnormal liver enzyme elevations. - Hypoglycaemia: when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: long‑term therapy may reduce B12 absorption. - Acute renal failure: especially in patients with pre‑existing kidney disease.

Before initiating Metformin Pharmconsul, clinicians should assess patient‑specific risk factors and monitor relevant clinical parameters.

- Renal function assessment: evaluate eGFR and avoid use if severely impaired. - Hepatic function monitoring: check liver enzymes in patients with liver disease. - Lactic acidosis risk: avoid in conditions predisposing to hypoxia or tissue hypoperfusion. - Elderly patients: start at lower doses and monitor tolerance closely. - Concomitant medication review: assess for drugs that may affect renal clearance. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Pharmconsul can interact with several medicines, altering its plasma concentration or increasing the risk of adverse events.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute kidney injury, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma levels, enhancing toxicity. - Alcohol excess: potentiates lactic acidosis, especially in renal impairment.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Diuretics: can reduce renal clearance, necessitating monitoring of renal parameters. - Beta‑blockers: may mask hypoglycaemic symptoms when used with other agents.